SOHO 2023 Eleventh Annual Meeting
Avatar

SOHO 2023 First Report of Phase 3 PhALLCON Study: Comparing Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL

By SOHO 2023 Eleventh Annual Meeting FEATURING Elias Jabbour
By SOHO 2023 Eleventh Annual Meeting FEATURING Elias Jabbour
87 views
October 4, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
04:02
Michael Burke

Updated Results from the BLAST and TOWER Studies: Safety and Efficac…

28:07
Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
06:49
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Ad…

Feat. M. Luskin
04:11
Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
37:03
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: ALL

Feat. E. Jabbour
27:47
City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam
31:00
Louisville Hematology Highlights

Current Approaches in the Frontline Treatment of Adult ALL

Feat. N. Short
28:57
Total Health

Highlights From Key Hematology Trials at ASCO® 2023

Feat. J. Strauss
48:05
Yale Cancer Center

ALL - Progress in Research and Therapy in 2022

Feat. H. Kantarjian
17:38
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Curative Potential of CAR T-Cell Therapy for ALL

Feat. S. Grupp
18:39
Fred Hutchinson Cancer Center

MRD Positivity in ALL: Next Steps in Clinical Approach

Feat. R. Cassaday
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan